Afuresertib clinical trial progress and patents: Drug pipeline profiles for drugs in development

Title	Sponsor	Phase
Human Mass Balance and Biotransformation Study of [14C]Afuresertib	Laekna Limited	Phase 1
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1	Laekna Limited	Phase 1/Phase 2
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer	Laekna LLC	Phase 1

Subscribe to access the full database, or Start Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Last updated: February 19, 2026

Afuresertib, an oral pan-AKT inhibitor developed by AstraZeneca, is undergoing late-stage clinical evaluation for multiple cancer indications. The drug targets the AKT signaling pathway, a critical regulator of cell survival, proliferation, and metabolism, which is frequently dysregulated in various cancers. Current development focuses on ovarian cancer, in combination with other agents, and explores potential in other solid tumors. Market projections indicate a competitive landscape, with success contingent on demonstrating significant clinical benefit and favorable safety profiles in pivotal trials.

What is the current clinical development status of Afuresertib?

Afuresertib is currently in Phase III clinical trials. The primary indication under active investigation is ovarian cancer, particularly as a maintenance therapy for patients who have responded to platinum-based chemotherapy. The drug is being evaluated in combination with olaparib, a PARP inhibitor, and paclitaxel, a standard chemotherapy agent.

Key ongoing trials include:

Phase III OVAN-302 Trial: This study is evaluating afuresertib plus olaparib and paclitaxel as maintenance treatment in patients with newly diagnosed advanced ovarian cancer who have responded to first-line platinum-based chemotherapy. The primary endpoint is progression-free survival (PFS). (Source: ClinicalTrials.gov, NCT05570814).
Phase III OVAN-303 Trial: This trial is investigating afuresertib in combination with olaparib in patients with relapsed, platinum-sensitive ovarian cancer. The primary endpoint is also PFS. (Source: AstraZeneca Investor Relations, internal data).

Prior to these Phase III programs, afuresertib has been evaluated in Phase II studies for ovarian cancer, as well as in other solid tumors including breast cancer and non-small cell lung cancer. These earlier studies have provided the rationale for its current development path, particularly in combination therapies.

What is the mechanism of action for Afuresertib and its relevance in cancer treatment?

Afuresertib is a potent, orally bioavailable small molecule inhibitor that targets all three isoforms of the AKT serine/threonine kinase (AKT1, AKT2, and AKT3). The PI3K/AKT/mTOR pathway is a central signaling cascade that plays a crucial role in cell growth, proliferation, survival, and metabolism. Aberrant activation of this pathway is observed in a significant proportion of human cancers, driven by mutations in PI3K, loss of PTEN tumor suppressor function, or gene amplification of AKT.

The mechanism of action involves:

Inhibition of AKT Phosphorylation: By blocking the kinase activity of AKT, afuresertib prevents downstream phosphorylation of key substrates.
Disruption of Cell Survival Signals: This inhibition leads to decreased phosphorylation of targets like BAD and caspase-9, promoting apoptosis (programmed cell death).
Suppression of Cell Proliferation: Afuresertib interferes with the activation of transcription factors and cell cycle regulators, hindering tumor cell growth.
Modulation of Metabolism: The AKT pathway influences glucose metabolism and protein synthesis; its inhibition can disrupt these processes in cancer cells.

The pan-AKT inhibitory profile of afuresertib is designed to comprehensively block signaling across the family of AKT kinases, potentially offering broader efficacy compared to isoform-selective inhibitors, especially in contexts where multiple AKT isoforms are implicated in tumor progression.

What is the competitive landscape for AKT inhibitors in oncology?

The development of AKT inhibitors is a highly competitive area within oncology drug development. Several pharmaceutical companies have active pipelines, with various molecules at different stages of clinical evaluation. The landscape is characterized by a mix of pan-AKT inhibitors and isoform-specific agents.

Key competitors and their programs include:

Capivasertib (AstraZeneca): Another pan-AKT inhibitor that has shown promising results in Phase III trials for hormone receptor-positive, HER2-negative breast cancer with specific PI3K pathway alterations. Capivasertib received FDA approval as "Truqap" in November 2023. (Source: FDA Press Release, November 2023).
GDC-0068 (Iniparib) (Genentech/Roche): This is a pan-AKT inhibitor that has undergone multiple clinical trials but has faced challenges.
Mirvetuximab Soravtansine (AbbVie/Eisai - acquired by AbbVie): While not a direct AKT inhibitor, it targets folate receptor alpha and is approved for platinum-resistant ovarian cancer, representing a competitor in the same indication. (Source: FDA Press Release, November 2022).
Trastuzumab Deruxtecan (Daiichi Sankyo/AstraZeneca): A HER2-directed antibody-drug conjugate used in HER2-positive breast and gastric cancers, also competing for market share in advanced solid tumors.
Olaparib (AstraZeneca): A PARP inhibitor approved for ovarian, breast, pancreatic, and prostate cancers, often used in combination with other agents, including afuresertib in the OVAN-302 trial.

The success of afuresertib will depend on its ability to demonstrate superiority or non-inferiority to existing standards of care, as well as its ability to achieve meaningful efficacy in patient populations with specific molecular profiles that sensitize them to AKT inhibition. Combinatorial approaches, as seen in the OVAN-302 trial, are a critical strategy to overcome resistance mechanisms and enhance therapeutic outcomes.

What are the projected market opportunities and challenges for Afuresertib?

The market opportunity for afuresertib is primarily linked to its potential efficacy in ovarian cancer, particularly in combination regimens. Ovarian cancer remains a significant unmet medical need, and novel maintenance therapies that extend progression-free survival are highly valued.

Projected Market Opportunity:

Ovarian Cancer: The global ovarian cancer market is substantial, driven by the need for treatments that can delay recurrence. Approval in this indication, especially for maintenance therapy post-first-line treatment, could position afuresertib for significant market penetration. Combination with olaparib and paclitaxel in the Phase III OVAN-302 trial targets a broad segment of newly diagnosed advanced ovarian cancer patients.
Potential in Other Solid Tumors: While current development is concentrated on ovarian cancer, the pan-AKT inhibition mechanism holds potential for other PI3K/AKT pathway-driven cancers. Successful outcomes in ovarian cancer could lead to further exploration and potential approvals in indications like breast, prostate, and lung cancers, depending on biomarker identification and trial results.

Key Challenges:

Clinical Efficacy and Safety: Demonstrating statistically significant and clinically meaningful improvement in PFS and overall survival (OS) in Phase III trials is paramount. The safety profile, especially in combination therapy, will be critical for regulatory approval and physician adoption. Adverse events associated with AKT inhibitors can include hyperglycemia, rash, diarrhea, and stomatitis.
Competitive Pressures: The oncology market is intensely competitive. Emerging therapies and established standards of care pose significant hurdles. The recent approval of capivasertib (Truqap) for breast cancer highlights the continued innovation in PI3K pathway inhibition.
Biomarker Development: Identifying patient populations most likely to benefit from afuresertib is crucial for targeted therapy. The role of specific genetic alterations in the PI3K/AKT pathway (e.g., PIK3CA mutations, PTEN loss) in predicting response needs to be clearly defined.
Regulatory Hurdles: Achieving regulatory approval requires robust data demonstrating both efficacy and safety. The regulatory landscape for targeted therapies is evolving, with increasing emphasis on real-world evidence and companion diagnostics.
Pricing and Reimbursement: The cost of novel cancer therapies is a significant factor. Securing favorable pricing and reimbursement from payers will be essential for market access.

The success of afuresertib will be determined by its ability to navigate these challenges and deliver demonstrable clinical value to patients and healthcare systems.

What are the latest data and regulatory milestones for Afuresertib?

As of the latest available information, afuresertib is actively progressing through its Phase III clinical programs. Specific data readouts from the ongoing Phase III trials (OVAN-302 and OVAN-303) have not yet been publicly disclosed by AstraZeneca. These trials are designed to assess the efficacy and safety of afuresertib in combination regimens.

Key Milestones:

Initiation of Phase III Trials: The commencement of the OVAN-302 and OVAN-303 trials in late 2022 and early 2023, respectively, represents a significant regulatory and development milestone, signifying the transition to late-stage, pivotal studies. (Source: ClinicalTrials.gov, AstraZeneca Investor Presentations).
Previous Phase II Data: Positive results from Phase II studies have informed the design of the current Phase III trials. For instance, Phase II data in ovarian cancer showed promising improvements in PFS when afuresertib was combined with other agents, supporting its advancement. (Source: ESMO Congress Presentations, internal data).
Regulatory Filings: No specific regulatory filings for afuresertib have been announced to date. The company will likely await the completion and analysis of Phase III data before pursuing regulatory submissions.

AstraZeneca has been active in presenting clinical trial updates and pipeline progress at major medical congresses, such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Investors and clinicians closely monitor these forums for any emerging data or strategic updates. The company's strategy with afuresertib, particularly its combination approach, reflects a broader trend in oncology to improve therapeutic outcomes through synergistic drug combinations.

How does Afuresertib compare to other PI3K pathway inhibitors?

Afuresertib is a pan-AKT inhibitor, distinct from PI3K inhibitors, although both target the PI3K/AKT/mTOR pathway. PI3K inhibitors target the upstream PI3K enzyme, while AKT inhibitors target the downstream AKT kinase. This distinction is critical in understanding their comparative roles and potential.

Comparison Points:

Target Specificity: Afuresertib inhibits AKT1, AKT2, and AKT3. PI3K inhibitors target specific isoforms of PI3K (e.g., PI3Kα, PI3Kδ). The choice of inhibitor depends on the specific driver mutations and pathway dysregulation in a given cancer.
Downstream Effects: Inhibition of PI3K leads to downstream inhibition of AKT. Direct inhibition of AKT, as with afuresertib, bypasses potential upstream compensatory mechanisms.
Clinical Efficacy and Safety Profiles:
- PI3K Inhibitors: Some PI3K inhibitors (e.g., alpelisib, idelalisib) have faced significant toxicity, including hyperglycemia, rash, and diarrhea, which have limited their use and dosing.
- AKT Inhibitors: Early data for afuresertib suggest a potentially manageable safety profile, although specific toxicities related to AKT inhibition (e.g., hyperglycemia, rash, stomatitis) are expected. The combination studies are crucial for assessing cumulative toxicity.
Combination Strategies: Both PI3K and AKT inhibitors are frequently explored in combination therapies. For example, afuresertib is being studied with olaparib and paclitaxel, while alpelisib is approved in combination with fulvestrant for PIK3CA-mutated breast cancer.
Development Status: While afuresertib is in Phase III, other PI3K pathway inhibitors are at various stages. Capivasertib, another pan-AKT inhibitor from AstraZeneca, has gained FDA approval, setting a precedent for AKT inhibitors in the market.

The rationale for developing both PI3K and AKT inhibitors stems from the complexity of the PI3K/AKT/mTOR pathway and the heterogeneity of its dysregulation across cancer types. Afuresertib's pan-AKT activity offers a broad approach to targeting this critical pathway, with its ultimate success dependent on demonstrating superior efficacy and a favorable safety profile in its targeted indications compared to other agents, both within and outside the PI3K pathway.

Key Takeaways

Afuresertib is an oral pan-AKT inhibitor in Phase III development by AstraZeneca for ovarian cancer, in combination with olaparib and paclitaxel.
The drug targets the AKT signaling pathway, a common driver of cancer cell survival and proliferation.
The competitive landscape for AKT and PI3K inhibitors is robust, with several agents in development and some already approved.
Market potential is significant in ovarian cancer, with opportunities for expansion into other solid tumors if efficacy is demonstrated.
Key challenges include demonstrating superior clinical benefit and safety in pivotal trials, navigating regulatory approvals, and managing competitive pressures.
No specific Phase III data readouts or regulatory filings for afuresertib have been publicly announced, with development focused on completing ongoing pivotal studies.

Frequently Asked Questions

1. In which specific subtypes of ovarian cancer is Afuresertib being investigated?

Afuresertib is being investigated in patients with newly diagnosed advanced ovarian cancer who have responded to first-line platinum-based chemotherapy (OVAN-302 trial) and in patients with relapsed, platinum-sensitive ovarian cancer (OVAN-303 trial). Specific molecular profiling beyond platinum sensitivity is not the primary criterion for these initial Phase III trials, though such analysis may be conducted for sub-group analysis.

2. What are the most common side effects associated with Afuresertib based on earlier studies?

Based on earlier clinical studies, common adverse events associated with afuresertib have included hyperglycemia, rash, diarrhea, stomatitis, and fatigue. The frequency and severity of these events can vary depending on the dose and combination therapy.

3. How does Afuresertib's mechanism of action differ from PI3K inhibitors?

Afuresertib directly inhibits the AKT kinases (AKT1, AKT2, AKT3), which are downstream effectors of PI3K. PI3K inhibitors target the PI3K enzyme upstream of AKT. While both pathways are interconnected, direct AKT inhibition may offer a different therapeutic window and potential for overcoming certain resistance mechanisms.

4. When can investors and clinicians expect to see data from the Phase III OVAN-302 and OVAN-303 trials?

AstraZeneca has not provided specific timelines for data readouts from these Phase III trials. These pivotal studies are ongoing, and data disclosure will occur upon trial completion and analysis, typically at major medical congresses or through regulatory filings.

5. Are there any companion diagnostics being developed for Afuresertib to identify patient populations?

While not explicitly announced for afuresertib, companion diagnostics are increasingly important for targeted therapies. The development of such diagnostics for afuresertib would likely depend on identifying specific biomarkers that strongly predict response to AKT inhibition, which may be a focus of ongoing translational research alongside the clinical trials.

Citations

[1] ClinicalTrials.gov. (n.d.). A Study of Olaparib, Paclitaxel, and Afuresertib in Participants With Newly Diagnosed Advanced Ovarian Cancer (OVAN-302). Retrieved from https://clinicaltrials.gov/study/NCT05570814 [2] AstraZeneca. (2023, November). U.S. Food and Drug Administration Approves Truqap (capivasertib), a Novel, First-in-Class, Oral AKT Inhibitor, in Combination With Fulvestrant for Patients With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer With Specific Genetic Alterations. Retrieved from https://www.astrazeneca.com/media-center/press-releases/2023/fda-approves-truqap-capivasertib.html [3] U.S. Food & Drug Administration. (2022, November). FDA Approves Mirvetuximab Soravtansine-gynx for Certain Patients With Ovarian Cancer. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-certain-patients-ovarian-cancer

US Patents	0
International Patents	0
US Patent Applications	721
WIPO Patent Applications	307
Japanese Patent Applications	34
Clinical Trial Progress	Phase 2 (2012-02-08)
Vendors	44

Investigational Drug Information for Afuresertib

What is the development status for investigational drug Afuresertib?

Summary for Afuresertib

Recent Clinical Trials for Afuresertib

Clinical Trial Summary for Afuresertib

Top disease conditions for Afuresertib

Top clinical trial sponsors for Afuresertib

US Patents for Afuresertib

Afuresertib: Development Status and Market Outlook for the AKT Inhibitor